Last reviewed · How we verify
NCT03694054
Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers
NA trial testing Care coordination tool in Lung Cancer in 57 participants. Completed in 31 March 2019.
28 February 2019
Quick facts
| Lead sponsor | Geisinger Clinic |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 57 |
| Start date | 4 June 2018 |
| Primary completion | 28 February 2019 |
| Estimated completion | 31 March 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Care coordination tool
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Geisinger Clinic
Who can join
18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Oncology Care Coordination study is designed to evaluate use of a care coordination tool for lung cancer patients and their caregiver on quality of care and performance outcomes. Eligible patients need to be receiving treatment at Geisinger. Participation in the study involves completion of surveys, permission to review information from the patient's electronic health record, and for some enrollment in the care coordination tool called Harmonized Care. Geisinger oncology care providers who have patients enrolled the study will be invited for interviews.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03694054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Geisinger Clinic trials
Trials by the same sponsor.
- NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
- NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
- NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
- NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
- NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03694054 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
- Last refreshed: 9 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03694054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing